A number of other research firms have also recently commented on AMRS. Zacks Investment Research cut shares of Amyris from a hold rating to a sell rating in a research note on Tuesday, October 9th. B. Riley set a $10.00 target price on shares of Amyris and gave the stock a buy rating in a research note on Wednesday, October 3rd. Finally, BidaskClub upgraded shares of Amyris from a hold rating to a buy rating in a research note on Wednesday, August 15th. One analyst has rated the stock with a sell rating, one has issued a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of Buy and a consensus target price of $8.83.
NASDAQ AMRS opened at $4.34 on Tuesday. Amyris has a 12 month low of $3.19 and a 12 month high of $9.28.
Amyris (NASDAQ:AMRS) last released its earnings results on Tuesday, November 13th. The biotechnology company reported ($1.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.96). The business had revenue of $14.90 million for the quarter, compared to the consensus estimate of $46.72 million. During the same quarter last year, the firm posted ($0.81) EPS. The company’s revenue for the quarter was down 38.4% compared to the same quarter last year. On average, sell-side analysts expect that Amyris will post -1.34 earnings per share for the current year.
In other Amyris news, insider John Melo sold 5,195 shares of the firm’s stock in a transaction that occurred on Monday, October 15th. The shares were sold at an average price of $7.50, for a total transaction of $38,962.50. Following the sale, the insider now owns 743,713 shares in the company, valued at approximately $5,577,847.50. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Kathleen Valiasek bought 23,000 shares of the firm’s stock in a transaction on Tuesday, November 27th. The shares were purchased at an average price of $4.37 per share, for a total transaction of $100,510.00. Following the purchase, the chief financial officer now owns 251,630 shares in the company, valued at approximately $1,099,623.10. The disclosure for this purchase can be found here. 21.80% of the stock is currently owned by company insiders.
Institutional investors have recently added to or reduced their stakes in the company. Fox Run Management L.L.C. bought a new stake in shares of Amyris during the third quarter valued at approximately $121,000. Dynamic Technology Lab Private Ltd bought a new stake in shares of Amyris during the third quarter valued at approximately $127,000. B. Riley Wealth Management Inc. bought a new stake in shares of Amyris during the third quarter valued at approximately $159,000. Rhumbline Advisers bought a new stake in shares of Amyris during the second quarter valued at approximately $147,000. Finally, Bank of Montreal Can raised its position in shares of Amyris by 14,604.1% during the third quarter. Bank of Montreal Can now owns 25,291 shares of the biotechnology company’s stock valued at $202,000 after buying an additional 25,119 shares during the last quarter. Hedge funds and other institutional investors own 32.21% of the company’s stock.
Amyris Company Profile
Amyris, Inc provides various alternatives to a range of petroleum-sourced products worldwide. The company uses its industrial bioscience technology to design microbes primarily yeast, as well as to convert plant-sourced sugars into renewable ingredients. It produces and sells Biofene that converts to squalane, which is used as an emollient in cosmetics and other personal care products; and natural oils and aroma chemicals for the flavors and fragrances market.
Further Reading: Should you buy a closed-end mutual fund?
Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.